SCOPUS 정보 검색 플랫폼

Bioorganic and Medicinal Chemistry Letters

Volumn 11, Issue 14, 2001, Pages 1897-1902

Development of specific CXCR4 inhibitors possessing high selectivity indexes as well as complete stability in serum based on an anti-HIV peptide T140

(13) Tamamura, Hirokazu a Omagari, Akane a Hiramatsu, Kenichi a Gotoh, Kazuyo b Kanamoto, Taisei b Xu, Younong a Kodama, Eiichi a Matsuoka, Masao a Hattori, Toshio c Yamamoto, Naoki d Nakashima, Hideki b Otaka, Akira a Fujii, Nobutaka a

a KYOTO UNIVERSITY (Japan)

b KAGOSHIMA UNIVERSITY (Japan)

c TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE (Japan)

d TOKYO MEDICAL AND DENTAL UNIVERSITY (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ARGINYLARGINYL 3 (2 NAPHTHYL)ALANYLCYSTEINYLTYROSYLARGINYLLYSYL DEXTRO CITRULLYLPROLYLTYROSYLARGINYLCITRULLYLCYSTEINYLARGININAMIDE; ARGINYLARGINYL 3 (2 NAPHTHYL)ALANYLCYSTEINYLTYROSYLARGINYLLYSYL DEXTRO CITRULLYLPROLYLTYROSYLARGINYLCITRULLYLCYSTEINYLARGININE; ARGINYLARGINYL 3 (2 NAPHTHYL)ALANYLCYSTEINYLTYROSYLARGINYLLYSYL DEXTRO CITRULLYLPROLYLTYROSYLCITRULLYLCITRULLYLCYSTEINYLARGININAMIDE; ARGINYLARGINYL 3 (2 NAPHTHYL)ALANYLCYSTEINYLTYROSYLARGINYLLYSYL DEXTRO CITRULLYLPROLYLTYROSYLCITRULLYLCITRULLYLCYSTEINYLARGININE; ARGINYLARGINYL 3 (2 NAPHTHYL)ALANYLCYSTEINYLTYROSYLARGINYLLYSYL DEXTRO LYSYLPROLYLTYROSYLARGINYLCITRULLYLCYSTEINYLARGININAMIDE; ARGINYLARGINYL 3 (2 NAPHTHYL)ALANYLCYSTEINYLTYROSYLARGINYLLYSYLLYSYL DEXTRO LYSYLPROLYLTYROSYLARGINYLCITRULLYLCYSTEINYLARGININE; ARGINYLARGINYL 3 (2 NAPHTHYL)ALANYLCYSTEINYLTYROSYLCITRULLYLLYSL DEXTRO LYSYLPROLYLTYROSYLARGINYLCITRULLYLCYSTEINYLARGININE; ARGINYLARGINYL 3 (2 NAPHTHYL)ALANYLCYSTEINYLTYROSYLCITRULLYLLYSYL DEXTRO CITRULLYLPROLYLTYROSYLARGINYLCITRULLYLCYSTEINYLARGININE; ARGINYLARGINYL 3 (2 NAPHTHYL)ALANYLCYSTEINYLTYROSYLCITRULLYLLYSYL DEXTRO LYSYLPROLYLTYROSYLCITRULLYLCITRULLYLCYSTEINYLARGININAMIDE; ARGINYLARGINYL 3 (2 NAPHTHYL)ALANYLCYSTEINYLTYROSYLCITRULLYLLYSYL DEXTRO LYSYLPROLYLTYROSYLCITRULLYLCITRULLYLCYSTEINYLARGININE; CHEMOKINE RECEPTOR CXCR4; CITRULLYLARGINYL 3 (2 NAPHTHYL)ALANYLCYSTEINYLTYROSYLARGINYLLYSYL DEXTRO CITRULLYLPROLYLTYROSYLARGINYLCITRULLYLCYSTEINYLARGININAMIDE; CITRULLYLARGINYL 3 (2 NAPHTHYL)ALANYLCYSTEINYLTYROSYLARGINYLLYSYL DEXTRO CITRULLYLPROLYLTYROSYLARGINYLCITRULLYLCYSTEINYLARGININE; CITRULLYLARGINYL 3 (2 NAPHTHYL)ALANYLCYSTEINYLTYROSYLARGINYLLYSYL DEXTRO LYSYLPROLYLTYROSYLCITRULLYLCITRULLYLCYSTEINYLARGININAMIDE; CITRULLYLARGINYL 3 (2 NAPHTHYL)ALANYLCYSTEINYLTYROSYLARGINYLLYSYL DEXTRO LYSYLPROLYLTYROSYLCITRULLYLCITRULLYLCYSTEINYLARGININE; CITRULLYLARGINYL 3 (2 NAPHTHYL)ALANYLCYSTEINYLTYROSYLCITRULLYLLYSYL DEXTRO LYSYLPROLYLTYROSYLARGINYLCITRULLYLCYSTEINYLARGININAMIDE; CITRULLYLARGINYL 3 (2 NAPHTHYL)ALANYLCYSTEINYLTYROSYLCITRULLYLLYSYL DEXTRO LYSYLPROLYLTYROSYLARGINYLCITRULLYLCYSTEINYLARGININE; T 140; T 140[6 CITRULLINE 8 DEXTRO CITRULLINE]; T 140[6 CITRULLINE]; TC 14003; TC 14005; TC 14011; TC 14012; TC 14013; TC 14014; TC 14015; TC 14016; TC 14017; TC 14018; TC 14019; TC 14020; TC 14021; TC 14022; TN 14003; TN 14005; TZ 14004; UNCLASSIFIED DRUG; ZIDOVUDINE;

AMIDATION; ANTIVIRAL ACTIVITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CAT; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG SELECTIVITY; DRUG STABILITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; INCUBATION TIME; NONHUMAN; T LYMPHOCYTE; VIRUS STRAIN;

ANIMALS; ANTI-HIV AGENTS; CATS; CELL SURVIVAL; CIRCULAR DICHROISM; CITRULLINE; DRUG STABILITY; HIV-1; HUMANS; INHIBITORY CONCENTRATION 50; OLIGOPEPTIDES; PEPTIDES; RECEPTORS, CXCR4;

FELIDAE; HUMAN IMMUNODEFICIENCY VIRUS 1;